Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1985 Sep 1;162(3):917–929. doi: 10.1084/jem.162.3.917

An analysis of in vitro T cell responsiveness in lepromatous leprosy

PMCID: PMC2187803  PMID: 3928804

Abstract

In lepromatous leprosy, there is extensive replication of Mycobacterium leprae (M. leprae) within dermal macrophages. This lack of microbial resistance has been attributed to a defective cell-mediated immune response to M. leprae antigens. We have examined the in vitro response of T cells to M. leprae to determine if hyporesponsiveness could be reversed. The study included 40 unselected patients from New York and from Colombia, most with the severe lepromatous form of the disease. We first noted that lepromatous leprosy patients were of two types: those unable to respond, as assessed by T cell proliferation and immune (gamma) interferon (IFN-gamma) release, and a second group, exhibiting low but detectable responses relative to tuberculoid controls. When the effect of exogenous recombinant interleukin-2 (IL-2) on the response to M. leprae antigens was compared in the two groups, many of the low responders, but not the nonresponders, showed enhanced proliferation and IFN-gamma release. To evaluate a possible suppressive effect of monocytes, these cells were eliminated with a cell-specific monoclonal antibody and complement. Depletion of monocytes often expanded preexisting weak responses but did not reverse the anergy of the M. leprae nonresponders. The enhancement was not M. leprae-specific, since it was also observed when bacillus Calmette-Guerin was the antigenic stimulus for proliferation and IFN-gamma production. Removal of the suppressor T cell subset, with OKT8 antibody and complement, also did not restore responses in nonresponder patients. We conclude that a sizable number of lepromatous leprosy patients exhibit a low degree of responsiveness to M. leprae and that the responses can be enhanced in vitro with IL-2 or with monocyte depletion. Nonresponsiveness, however, cannot be reversed. Since currently available assays measure the function of previously sensitized T cells, suppressor mechanisms may yet contribute to defective cell-mediated immunity by impairing the initial sensitization to M. leprae antigens.

Full Text

The Full Text of this article is available as a PDF (927.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abramson C. S., Kersey J. H., LeBien T. W. A monoclonal antibody (BA-1) reactive with cells of human B lymphocyte lineage. J Immunol. 1981 Jan;126(1):83–88. [PubMed] [Google Scholar]
  2. Birdi T. J., Mistry N. F., Mahadevan P. R., Antia N. H. Alterations in the membrane of macrophages from leprosy patients. Infect Immun. 1983 Jul;41(1):121–127. doi: 10.1128/iai.41.1.121-127.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Closs O., Reitan L. J., Negassi K., Harboe M., Belehu A. In vitro stimulation of lymphocytes in leprosy patients, healthy contacts of leprosy patients, and subjects not exposed to leprosy. Comparison of an antigen fraction prepared from Mycobacterium leprae and tuberculin-purified protein derivative. Scand J Immunol. 1982 Aug;16(2):103–115. doi: 10.1111/j.1365-3083.1982.tb00704.x. [DOI] [PubMed] [Google Scholar]
  4. Godal T. Immunological aspects of leprosy--present status. Prog Allergy. 1978;25:211–242. [PubMed] [Google Scholar]
  5. Godal T., Myklestad B., Samuel D. R., Myrvang B. Characterization of the cellular immune defect in lepromatous leprosy: a specific lack of circulating Mycobacterium leprae-reactive lymphocytes. Clin Exp Immunol. 1971 Dec;9(6):821–831. [PMC free article] [PubMed] [Google Scholar]
  6. Haregewoin A., Godal T., Mustafa A. S., Belehu A., Yemaneberhan T. T-cell conditioned media reverse T-cell unresponsiveness in lepromatous leprosy. Nature. 1983 May 26;303(5915):342–344. doi: 10.1038/303342a0. [DOI] [PubMed] [Google Scholar]
  7. Haregewoin A., Mustafa A. S., Helle I., Waters M. F., Leiker D. L., Godal T. Reversal by interleukin-2 of the T cell unresponsiveness of lepromatous leprosy to Mycobacterium leprae. Immunol Rev. 1984 Aug;80:77–86. doi: 10.1111/j.1600-065x.1984.tb00495.x. [DOI] [PubMed] [Google Scholar]
  8. Horwitz M. A., Levis W. R., Cohn Z. A. Defective production of monocyte-activating cytokines in lepromatous leprosy. J Exp Med. 1984 Mar 1;159(3):666–678. doi: 10.1084/jem.159.3.666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Mehra V., Brennan P. J., Rada E., Convit J., Bloom B. R. Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid. Nature. 1984 Mar 8;308(5955):194–196. doi: 10.1038/308194a0. [DOI] [PubMed] [Google Scholar]
  10. Mehra V., Convit J., Rubinstein A., Bloom B. R. Activated suppressor T cells in leprosy. J Immunol. 1982 Nov;129(5):1946–1951. [PubMed] [Google Scholar]
  11. Mehra V., Mason L. H., Fields J. P., Bloom B. R. Lepromin-induced suppressor cells in patients with leprosy. J Immunol. 1979 Oct;123(4):1813–1817. [PubMed] [Google Scholar]
  12. Mehra V., Mason L. H., Rothman W., Reinherz E., Schlossman S. F., Bloom B. R. Delineation of a human T cell subset responsible for lepromin-induced suppression in leprosy patients. J Immunol. 1980 Sep;125(3):1183–1188. [PubMed] [Google Scholar]
  13. Narayanan R. B., Bhutani L. K., Sharma A. K., Nath I. T cell subsets in leprosy lesions: in situ characterization using monoclonal antibodies. Clin Exp Immunol. 1983 Mar;51(3):421–429. [PMC free article] [PubMed] [Google Scholar]
  14. Nath I., Van Rood J. J., Mehra N. K., Vaidya M. C. Natural suppressor cells in human leprosy: the role of HLA-D-identical peripheral lymphocytes and macrophages in the in vitro modulation of lymphoproliferative responses. Clin Exp Immunol. 1980 Nov;42(2):203–210. [PMC free article] [PubMed] [Google Scholar]
  15. Nathan C. F., Murray H. W., Wiebe M. E., Rubin B. Y. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983 Sep 1;158(3):670–689. doi: 10.1084/jem.158.3.670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nathan C., Nogueira N., Juangbhanich C., Ellis J., Cohn Z. Activation of macrophages in vivo and in vitro. Correlation between hydrogen peroxide release and killing of Trypanosoma cruzi. J Exp Med. 1979 May 1;149(5):1056–1068. doi: 10.1084/jem.149.5.1056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nogueira N., Cohn Z. A. Trypanosoma cruzi: in vitro induction of macrophage microbicidal activity. J Exp Med. 1978 Jul 1;148(1):288–300. doi: 10.1084/jem.148.1.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nogueira N., Kaplan G., Levy E., Sarno E. N., Kushner P., Granelli-Piperno A., Vieira L., Colomer Gould V., Levis W., Steinman R. Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2. J Exp Med. 1983 Dec 1;158(6):2165–2170. doi: 10.1084/jem.158.6.2165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ottenhoff T. H., Elferink D. G., de Vries R. R. Unresponsiveness to Mycobacterium leprae in lepromatous leprosy in vitro: reversible or not? Int J Lepr Other Mycobact Dis. 1984 Sep;52(3):419–424. [PubMed] [Google Scholar]
  20. Ottenhoff T. H., Gonzalez N. M., de Vries R. R., Convit J., van Rood J. J. Association of HLA specificity LB-E12 (MB1, DC1, MT1) with lepromatous leprosy in a Venezuelan population. Tissue Antigens. 1984 Jul;24(1):25–29. doi: 10.1111/j.1399-0039.1984.tb00393.x. [DOI] [PubMed] [Google Scholar]
  21. Reinherz E. L., Kung P. C., Goldstein G., Levey R. H., Schlossman S. F. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1588–1592. doi: 10.1073/pnas.77.3.1588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ridley D. S., Jopling W. H. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966 Jul-Sep;34(3):255–273. [PubMed] [Google Scholar]
  23. Salgame P. R., Mahadevan P. R., Antia N. H. Mechanism of immunosuppression in leprosy: presence of suppressor factor(s) from macrophages of lepromatous patients. Infect Immun. 1983 Jun;40(3):1119–1126. doi: 10.1128/iai.40.3.1119-1126.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sathish M., Bhutani L. K., Sharma A. K., Nath I. Monocyte-derived soluble suppressor factor(s) in patients with lepromatous leprosy. Infect Immun. 1983 Dec;42(3):890–899. doi: 10.1128/iai.42.3.890-899.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Stoner G. L., Mshana R. N., Touw J., Belehu A. Studies on the defect in cell-mediated immunity in lepromatous leprosy using HLA-D-identical siblings. Absence of circulating suppressor cells and evidence that the defect is in the T-lymphocyte, rather than the monocyte, population. Scand J Immunol. 1982 Jan;15(1):33–48. doi: 10.1111/j.1365-3083.1982.tb00619.x. [DOI] [PubMed] [Google Scholar]
  26. Van Voorhis W. C., Hair L. S., Steinman R. M., Kaplan G. Human dendritic cells. Enrichment and characterization from peripheral blood. J Exp Med. 1982 Apr 1;155(4):1172–1187. doi: 10.1084/jem.155.4.1172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Van Voorhis W. C., Kaplan G., Sarno E. N., Horwitz M. A., Steinman R. M., Levis W. R., Nogueira N., Hair L. S., Gattass C. R., Arrick B. A. The cutaneous infiltrates of leprosy: cellular characteristics and the predominant T-cell phenotypes. N Engl J Med. 1982 Dec 23;307(26):1593–1597. doi: 10.1056/NEJM198212233072601. [DOI] [PubMed] [Google Scholar]
  28. Van Voorhis W. C., Steinman R. M., Hair L. S., Luban J., Witmer M. D., Koide S., Cohn Z. A. Specific antimononuclear phagocyte monoclonal antibodies. Application to the purification of dendritic cells and the tissue localization of macrophages. J Exp Med. 1983 Jul 1;158(1):126–145. doi: 10.1084/jem.158.1.126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Waldorf D. S., Sheagren J. N., Trautman J. R., Block J. B. Impaired delayed hypersensitivity in patients with lepromatous leprosy. Lancet. 1966 Oct 8;2(7467):773–776. doi: 10.1016/s0140-6736(66)90366-7. [DOI] [PubMed] [Google Scholar]
  30. Young D. B., Buchanan T. M. A serological test for leprosy with a glycolipid specific for Mycobacterium leprae. Science. 1983 Sep 9;221(4615):1057–1059. doi: 10.1126/science.6348948. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES